Rani Therapeutics Holdings Inc (NASDAQ:RANI) gapped up before the market opened on Friday . The stock had previously closed at $19.56, but opened at $19.98. Rani Therapeutics shares last traded at $19.95, with a volume of 891 shares traded.
Separately, Zacks Investment Research raised shares of Rani Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 8th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $25.40.
The firm’s 50 day moving average price is $22.76.
Hedge funds have recently bought and sold shares of the company. UBS Group AG bought a new position in shares of Rani Therapeutics in the third quarter worth about $55,000. Geode Capital Management LLC bought a new position in Rani Therapeutics in the 3rd quarter valued at approximately $385,000. Millennium Management LLC bought a new position in Rani Therapeutics in the 3rd quarter valued at approximately $517,000. Squarepoint Ops LLC bought a new position in Rani Therapeutics in the 3rd quarter valued at approximately $891,000. Finally, Goldman Sachs Group Inc. bought a new position in Rani Therapeutics in the 3rd quarter valued at approximately $1,081,000.
Rani Therapeutics Company Profile (NASDAQ:RANI)
Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company. It focused on advancing technologies to enable the development of orally administered biologics. Rani Therapeutics Holdings Inc is based in SAN JOSE, Calif.
Read More: How to start trading in the forex market?
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.